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Summary 
Resistance  to Leishmania  major in mice is associated with the appearance  of distinct T  helper 
type 1 (Thl) and Th2 subsets. T cells from lymph nodes draining cutaneous lesions of resistant 
mice are primarily interferon 31 (IFN-3,)-producing Thl cells. In contrast, T calls from susceptible 
mice are principally Th2 cells that generate interleukin 4 (IL-4).  Although existing evidence 
is supportive of a role for IFN-qr in the generation of Thl cells, additional factors may be required 
for a protective response to be maintained. A potential candidate is IL-12, a heterodimeric cytokine 
produced by monocytes and B cells that has multiple effects on T and natural killer call function, 
including inducing IFN-'y production. Using an experimental leishmanial model we have observed 
that daily intraperitoneal administration at the time of parasite challenge of either 0.33 ~g IL-12 
(a consecutive 5 d/wk for 5 wk) or 1.0/~g IL-12 per mouse (only a consecutive 5 d) caused 
a >75% reduction in parasite burden at the site of infection, in highly susceptible BALB/c mice. 
Delay of treatment by 1 wk had less of a protective effect. Concomitant with these protective 
effects was an increase in IFN-~/and a decrease in IL-4 production, as measured by enzyme-linked 
immunosorbent assay of supernatants generated from popliteal lymph node cells stimulated with 
leishmanial antigen in vitro. The reduction in parasite numbers induced by IL-12 therapy was 
still apparent at 10 wk postinfection. In addition, we observed that the administration of a rabbit 
anti-recombinant murine IL-12 polyclonal antibody (200/~g i.p. every other day for 25 d) at 
the time of infection to resistant C57BI/6 mice exacerbated disease. These effects were accompanied 
by a shift in IFN-7 production in vitro by antigen-stimulated lymph node cells indicative of 
a Th2-1ike response. These findings suggest that IL-12 has an important role in initiating a Thl 
response and protective immunity. 
T 
he outcome of experimental infection in inbred strains of 
mice  infected  with  Leishmania  major  is  profoundly 
influenced by the nature of the CD4 + T cell response to the 
disease. Disease resistance and susceptibility appear to depend 
on  the  cytokine profile secreted  by particular  subsets  of 
CD4 + lymphocytes. In mouse strains  that develop  small 
localized lesions that ultimately resolve, exemplified by the 
C57B1/6 mouse, resistance is preferentially associated with 
the presence of IFN-7-producing CD4 + cells of the Thl 
subset (1). In mice that develop a progressive and ultimately 
fatal infection, characterized  by the BALB/c mouse, suscep- 
tibility is preferentially associated with the presence of IL-4- 
producing T cells of the Th2 subset (1). It has been directly 
demonstrated by adoptive transfer of specific Thl and Th2 
cell lines that these T cell subsets mediate disease resistance 
or susceptibility (2). A causal relationship between cytokine 
production and disease outcome is further suggested by the 
observation that anti-IL-4 treatment attenuates disease in sus- 
ceptible mice (3), while anti-IFN-7 antibody treatment in- 
duces susceptibility in otherwise resistant mice (4). The ob- 
servation, however, that administration of IFN-3' to BALB/c 
mice after  the initiation of infection does not modify the 
progression of disease (3, 5) suggests that factors other than 
IFN-y alone are necessary for the development of a durable 
Thl response. 
IL-12, also known as natural killer cell stimulating factor 
(NKSF) and cytotoxic lymphocyte  maturation factor (CLMF), 
is a heterodimeric cytokine produced by monocytes and B 
cells (6-8).  It displays a potent array of biological activities 
affecting NK and T cells. These biological activities include 
the ability to enhance proliferation of NK and T  cells, to 
induce production of IFN-% and to enhance NK and T cell 
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manial model is the observation that IL-12 can promote the 
development of Thl cells (11a). 
In this study, we examine the effects of recombinant mu- 
fine (rm)IL-12 administration on the immune response to 
cutaneous leishmaniasis in highly susceptible  BALB/c mice. 
Conversely, we also examine the effects of anti-rmlL-12 anti- 
body therapy in resistant C57B1/6 mice. We demonstrate that 
IL-12 plays a critical role in the development of a protective 
Thl immune response and in controlling the progression of 
chronic disseminating leishmaniasis in these animal models. 
Materials  and Methods 
Leishmania.  L. major, National Institutes of Health Seidman 
strain (WHOM/SN/74 Seidman), was used in these investigations 
(12). Amastigotes were propagated in mice by serial infection and 
obtained from infected footpad tissue as described (13). 
Animals and Infection.  Female  BALB/cJ  (H-2a; amastignte and 
lymphocyte donors) and C57B1/6 (H-2b; lymphocyte  donors) mice 
were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Mice were infected subcutaneously into each hind footpad with 
a 0.05-ml suspension of 2  x  10  s tissue-derived amastigotes (13) 
in 0.15 M NaC1. 
NKSF/IL.12.  Serum-free  culture supernatant was collected  and 
purified from Chinese hamster ovary cells stably transfected with 
amplified cDNAs for the p40 and p35 subunits of raiL-12. SDS- 
PAGE analysis  revealed this preparation to consist predominantly 
of mlb12 heterodimeric  (95 %) with a small amount of  monomeric 
p40 subunit (5 % ). rml-L-12  was stored  in 500-/~g aliquots  of  calcium- 
and magnesium-free  modified  Dulbecco's PBS at -80~  until used. 
The specific activity was '~7.8  x  106 U/rag. 1 U is defined rela- 
tive to a human IL-12 standard RB 012892 in a PHA blast prolifer- 
ation assay. 1 U is approximately equal to the amount that yields 
half-maximal stimulation. Endotoxin levels as measured by the 
Limulus amebocyte lysate assay did not exceed 0.5-0.9 EU/mg. 
In  Vivo 11:12 Treatment.  In  the  initial study BALB/c mice 
(n  =  5 per treatment group) were given rmlL-12 (0.11/~g/d or 
0.33/~g/d) or 0.9% NaC1 (Abbott Laboratories, N. Chicago, IL) 
by single intraperitoneal administration for a consecutive 5 d/wk 
for 5 wk after a challenge with amastigotes in both hind footpads. 
At 1-wk time intervals during the 5 wk, lesion development was 
monitored by measuring with a venier caliper footpad thickness 
of infected footpads. 
In the second study BALB/c  mice (n ,= 10 per treatment group) 
were administered rmlL-12 intraperitoneally in  the  following 
manner. Immediately  after a challenge  with amastigotes  in the hind 
footpads, one group received  0.33/xg/d rmlb12 for a consecutive 
5 d/wk for 5 wk, or alternatively another group received saline 
alone in a similar manner. An additional group received 1.0 ~g/d 
traiL,12 for a consecutive 5 d for the first week of infection only, 
while with another group treatment with 1.0/~g/d rmlb12 was 
delayed until the second week of infection, where it was given for 
a consecutive  5 d/wk and continued for a total of 5 wk. Represen- 
tative animals  from each group at selected time intervals  were killed 
and  footpad  parasite  burdens were quantified  by  published 
methods (13). 
Neutralizing Rabbit Anti-rmll_,12 Antibody.  Female  New Zealand 
white rabbits were immunized subcutaneously with 50/~g  of 
rmlb12 in adjuvant bimonthly. An immune Ig fraction from an- 
tisera pooled from one rabbit (031302, anti-IL-12)  was obtained by 
binding to protein A-agarose  column (Repligen Corp., Cambridge, 
MA) according to established procedures (14, 15) using a FPLC 
chromatography system (Pharmacia Fine Chemicals, Piscataway, 
NJ). Purified antibody was stored at  -80~  until needed. This 
anti-l-b12 preparation  is not known to react with any other cytokines 
other than Ib12 (our unpublished observations). 
In Vivo  Anti-II.,12 Treatment.  After a challenge  with amastigotes 
in the hind footpads, C57B1/6 mice (n =  8 per treatment group) 
were treated with either anti-IL-12 antibody or normal rabbit Ig 
(I-5006; Sigma Chemical Co., St. Louis, MO) by intraperitoneal 
injection of 200/~g of either material commencing on the day of 
challenge and continued every  other day for 25 d. At selected time 
intervals parasite burdens were quantified as described above. 
Lymph Node Lymphocytes and Lympholeine-containing Culture Su- 
pernatants.  Lymph node lymphocytes  were obtained from draining 
popliteal lymph nodes of Leishmania-infected or normal mice as 
described (13). Lymphokine-containing culture supernatants were 
prepared by published  methods (16). Briefly,  cultures of  lymph node 
cells (106/ml) in RPMI supplemented  with 2.5% FCS serum (Hy- 
clone Laboratories, Logan, UT) were incubated at 37~  with ei- 
ther culture-derived  promastigotes,  tissue-derived  amastigotes, anti- 
CD3 mAb (145-2Cli, hamster IgG, 10/xg/ml; PharMingen, San 
Diego, CA), or left untreated. The cell-free  conditioned medium 
from lymph node cell cocultures  was harvested  after 48 h and stored 
at  -80~  until analyzed for activity. 
Immunoassays  for IFN-'y and 11.:4.  ELISAs  using mAbs specific 
for mlFN-',/(Genzyme Corp., Cambridge,  MA) or mlL-4 (Endogen 
Inc., Boston, MA) that have  been previously  described (17, 18) were 
used to quantify the amount of IFN-3' or I1.,4 present in culture 
supernatants of  lymph node cells cultured in vitro. A standard  curve 
for each  assay  was generated  with known concentrations  of mlFN-3' 
or mlb4 in protein-stabilized supplemented media. 
Results 
Treatment of BALB/c Mice with rralL-2 Affects Progression 
of  Lesion Development in Footpads Infected with Leishmania.  To 
assess whether administration of rmIL-12 could influence leish- 
manial parasite growth in BALB/c mice (susceptible  to cuta- 
neous hishmaniasis), footpad thickness was monitored in in- 
fected mice treated by intraperitoneal injection with saline, 
0.11 or 0.33/~g rmIL-12 once daily (qd), for a consecutive 
5 d/wk for 5 wk. Footpad thickness steadily increased in saline- 
treated animals during the 5-wk course. In contrast, at both 
doses of traiL-12, the increase in footpad thickness was re- 
duced. By the fifth week of infection, animals treated with 
0.11 or 0.33/~g traiL-12 had footpad thicknesses of 4.23  _+ 
0.25 and 3.07  _+  0.21  mm (n  =  5, mean  +_  SD), respec- 
tively. Footpad thickness in saline-treated animals was 5.60 
_+ 0.10 ram. These observations suggested that traiL-12 in- 
duced a reduction in parasite burden. Histological examina- 
tion of infected footpad tissue confirmed this conclusion (data 
not shown). 
Administration of rmlL-12 to BALB/c Mice during the First 
Week of Infection Is Sufficient to Induce Resistance to Leishmania. 
To determine the temporal sequence of  when rmlL-12 therapy 
was necessary to prevent lesion development, mice were in- 
fected by footpad injection and then treated with 1.0/~g 
rmlL-12 qd for a consecutive 5 d immediately after infec- 
tion, or treated with 1.0/~g qd beginning 1 wk after infec- 
tion. Mice given delayed therapy were administered rmIL-12 
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additional groups of infected mice or uninfected mice received 
0.33 #g rmlL-12 as described above,  and an infected group 
received saline. 
Parasite burdens in infected mice were determined by mi- 
croscopic examination of stained amastigote suspensions de- 
rived from infected footpad tissue (Table 1). At 5 wk postin- 
fection, parasite burden was reduced fivefold in mice treated 
continuously with 0.33 #g/d rmlL-12 when compared with 
saline-treated mice. More significantly, parasite reduction in 
mice treated with 1.0/~g rmlL-12 for the first week of infec- 
tion was 15-fold compared with saline controls. In contrast, 
parasite reduction was less than twofold in mice where treat- 
ment began  1 wk after infection. 
Treatment of mice for a consecutive 5 d postinfection was 
sufficient to prevent the development of footpad lesions. This 
protective effect of therapy was still apparent at 10 wk postin- 
fection (Table 1), suggesting that the induced antileishmanial 
effects were sustained. Treatment starting I wk after parasite 
challenge reduced the rate of lesion progression compared 
with saline-treated animals. These mice, however, remained 
susceptible so that by 8 wk lesion size approached that oh- 
Table  1.  Footpad  Parasite Burdens  from rralL-12-treated  BALB/c 
Mice Infected with Cutaneous Leishmaniasis for 5 and 10 wk 
Treatment  Amastigotes/mg tissue 
5th week  of infection 
Saline 
0.33/zg IL-12 
5 d/wk for 5 wk 
1.0 #g IL-12 
5 d/wk,  1st week only 
1.0 #g IL-12 
5 d/wk,  2nd to 5th week 
10th week of infection 
Saline 
0.33  #g IL-12 
5 d/wk for 5 wk 
1.0/zg IL-12 
5 d/wk,  1st week  only 
1.0 #g IL-12 
5 d/wk,  2nd to 5th week 
8.1  x  104+  2.4  x  104 
1.5  x  104+  5.1  x  103 
5.4  x  103-+ 2.1  x  103 
6.8  x  104+  2.3  x  104 
Dissemination  animals died 
2.8  x  103  +  5.5  x  103 
9.5  x  102+  9.3  x  102 
Dissemination  animals died 
BALB/c mice were infected  with L. major for 5-10 wk by injection  of 
2 x  10  s amastigotes/hind footpad. Mice were then treated with an in- 
traperitoneal injection  of saline or rmlL-12 qd starting on the day of in- 
fection for a consecutive 5 d/wk for 5 wk. In addition, one group was 
given rmlL-12 treatment for the first 5 d of infection, while in another 
group rmlL-12 was administered 1 wk after infection  for a consecutive 
5 d for 5 wk. After 5 or 10 wk representative  animals from  each group 
were killed  and parasite density  was quantified  by enumerating the num- 
ber  of parasites/mg of footpad tissue. Each value represents the 
mean _+ SD of three to five animals. 
ELISAs using mAbs specific  for mlFN"/or IL-4 were used to quantify 
the amount of IFN-7 and IL-4 present in culture supernatants of lymph 
node cells. Cells used were  derived  from popliteal  lymph nodes of  BALB/c 
mice infected  with L. major for 5 wk by injection of 2 x  10  s amasti- 
gotes/hind footpad. 
* Mice were treated  intraperitoneally  on the day of infection  with saline, 
or 0.33/~g/d rmlL-12 qd for a consecutive  5 d for 5 wk, or 1.0/~g/d 
rmlL-12 qd for a consecutive 5 d for the first week of infection only. 
* 106/ml lymph node cells were stimulated with 10  s amastigotes/ml or 
left untreated for 48 h in supplemented  media with 2.5% FCS. Cell-free 
supernatants were then collected and stored at  -80~  before being 
assayed. 
served in saline-treated controls at 4-5 wk of  infection, neces- 
sitating that the mice be killed. Administration of rmlL-12 
to uninfected mice did not  induce an  increase in  footpad 
swelling. 
Administration of  rmlL-12 at the Time of  Leishmania Infection 
in BALB/c Mice Alters  Cytokine Production.  To determine 
whether resistance affected by rmlL-12 was due to the gener- 
ation of a Thl response and the production of IFN-% the 
cytokine profile produced in vitro by draining popliteal lymph 
node cells of infected BALB/c mice was measured. At 5 wk 
postinfection, cells from mice treated with 0.33 #g/d rmlL-12 
or saline were stimulated in vitro with L. major amastigotes. 
IFN-'y production by lymph node cells of mice treated with 
traiL-12 was  10-fold  greater than that produced by saline- 
treated mice (Table 2). In contrast, cells from rmlL-12-treated 
mice produced fivefold less IL-4 than cells from saline con- 
trois. Semiquantitative PCR analysis of RNA from popliteal 
lymph node cells demonstrated that in vivo IFN-7 RNA levels 
in infected animals were increased by rmlL-12 treatment (10- 
fold increase compared with  untreated controls;  data  not 
shown). 
In addition, we observed that rmlL-12 treatment for 5 d 
postinfection appeared sufficient to initiate a protective Thl 
response early in infection (Table 1). To assess the cytokine 
profile produced under these conditions, popliteal lymph node 
cells were collected 5 wk postinfection from these treated 
mice and assayed as described above. In vitro IFN-~ produc- 
Table 2.  IFN-'y and 11.-4 Levels Present in Cellfree Supernatants 
from  Cultures of Lymph Node Cells Derived  from  rmlL-12- or 
Saline-treated BALB/c Mice Infected with Cutaneous Leishmaniasis 
for 5 wk under Various Culture Conditions 
In vivo  In vitro 
treatment*  treatment#  IFN-  7  IL-4 
pg/ml  pg/ml 
Saline  Untreated  1,500  150 
Amastigotes  1,500  )750 
0.33 #g/d  Untreated  8,000  25 
traiL-12,  5 wk  Amastigotes  >10,000  225 
1.0 #g/d  Untreated  8,000  0 
rmIL-12,  1 wk  Amastigotes  >10,000  75 
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tive 5 d immediately after infection was 10-fold greater than 
that of cells from saline-treated mice. Concomitantly, there 
was a 10-fold reduction in the level of IL-4 produced by these 
cells compared with saline controls (Table 2). Accompanying 
these changes we also observed a decrease in the relative per- 
centage of CD4 + T cells of the Th2 subset in the draining 
popliteal  lymph nodes  of treated  mice as  determined by 
immunophenotyping using anti-CD45R isotype antibody 
MB23G2/15Cll  (19, data not shown). 
Treatment of C57B1/6 Mice with Rabbit anti-rmlL-12 anti- 
body Abrogates Natural Resistance to L. major.  The observa- 
tion  above that rmlL-12 induces resistance in  susceptible 
BALB/c mice suggested that host production of IL-12 might 
be responsible for protection in a resistant mouse strain. To 
test  this  hypothesis,  mice from a resistant  mouse strain, 
C57B1/6, were administered polyclonal rabbit anti-rmlL-12 
antiserum beginning at the time of infection with L. major. 
Infected footpad tissues of C57B1/6 mice administered normal 
rabbit Ig had minimal swelling by 3 wk postinfection that 
returned to nearly baseline by 6 wk. In contrast, mice treated 
with anti-rmlL-12 antiserum developed large nonhealing le- 
sions. By 4 wk postinfection,  these footpads were twice as 
large as that of control animals and nearly as large as those 
of susceptible BALB/c mice. Examination of  parasite suspen- 
sions  derived  from footpad tissue  at  5  wk postinfection 
confirmed that footpad swelling was associated  with increased 
parasite burden (>70%  increase compared with untreated 
Table  3.  IFN-'y Levels Present CeU-free Sut~rnatants  from Cultures 
of Lymph Node Cells Derived from Anti-traiL-12- or Normal 
Sera-treated C57B1/6 Mice Infected with Cutaneous Leishmaniasis 
for 1-2 wk under Various Culture Conditions 
In vivo  In vitro 
treatment*  treatments*  IFN-3/ 
pg/ml 
Normal rabbit  Untreated  250 
Ig  Amastigotes  500 
Promastigotes  8,000 
Anti-CD3  500 
Rabbit anti-  Untreated  250 
rmlL-12  Amastigotes  250 
Promastigotes  3,000 
Anti-CD3  175 
ELISAs using mAbs specific for mlFN3~ were used. Cells were derived 
from  popliteal  lymph nodes of C57B1/6 mice infected with L.  major 
amastigotes for  1-2 wk. 
* Mice were treated intraperitoneally  on the day of infection with 200 
/~g normal rabbit Ig or rabbit anti-rmlL-12 qd and every other day there- 
after for 25 d. 
Lymph node cells were  stimulated  with amastigotes,  promastigotes, 
anti-CD3 mAb, or left untreated for 48 h in supplemented media. Su- 
pernatants  were  collected and stored at  -80~  before analysis. 
controls; 4.9  x  104  _+  1.9  x  103 amastigotes/mg tissue and 
1.3  x  103  _+  3.6  x  103  amastigotes/mg tissue  [n  =  3, 
mean  +_  SD],  respectively). 
The increased  disease susceptibility suggested that adminis- 
tration of anti-rmlL-12 antisera to C57B1/6 mice resulted 
in the inhibition of their normal Thl response to infection. 
To test this hypothesis, we measured in vitro the capacity 
of popliteal lymph node cells to produce IFN-% At 1-2 wk 
postinfection,  there was a >50% decrease in IFN-~/produc- 
tion by lymph node cells from anti-rmlL-12-treated mice when 
compared with cells from control antisera-treated  animals 
(Table 3). These observations taken together with those above 
demonstrate that the presence of IL-12 at the time of infec- 
tion is crucial in determining whether a Thl or Th2 response 
develops, and in the control of progressive disease. 
Discussion 
CD4 §  T  ceils can  be delineated  on the basis of their 
cytokine profile into two subsets, Thl and Th2, Thl cells 
produce IL-2 and IFN-'y in response to stimulation,  while 
Th2 cells produce IL-4,  IL-5,  and IL-10 (20). Additional 
cytokines are also produced by both these subsets. These subsets 
are thought to arise from a common precursor after stimula- 
tion via their TCRs (21). The mechanisms favoring the de- 
velopment of ThI and Th2 cels and which factors  or cytokines 
determine this differentiation  are not well defined. 
In mouse models of cutaneous leishmaniasis, a spectrum 
of disease ranging from self-healing cutaneous ulceration to 
progressive visceral dissemination occurs in association with 
distinct  lymphokine responses. In particular,  resolution of 
cutaneous disease requires the expansion of spedfic Thl cells 
that produce IFN-y, while exacerbation of infection requires 
the expansion of specific Th2 cells that produce IL-4 (1, 2). 
In this report, we provide evidence that IL-12 has a major 
role in influencing the development of a protective Thl im- 
mune response in L.  major infection.  We show that treat- 
ment with traiL-12 in BALB/c mice reverses their suscepti- 
bility to infection (Table 1). This alteration in susceptibility 
is due to a shift in the T cell response from a predominant 
Th2- to a Thl-type response (Table 2). Accompanying changes 
in IFN-3' and IL-4 levels produced by draining lymph node 
cells upon in vitro restimulation from these mice confirm 
that the IL-12-treated mice produce a more Thl-like response. 
Two sets of data pinpoint the time most critical for the 
presence of IL-12 in the resolution of  L. major disease. When 
IL-12 is administered only during the first week of infection, 
we observe resolution of infection. These data suggest that 
clearance of parasites from cutaneous tissues of BALB/c mice 
early after infection is influenced by IL-12. When treatment 
was delayed until the second week of infection, the animals 
were not able to heal the infection although disease progres- 
sion was delayed. Thus, the presence of IL-12 during the ini- 
tial parasite host-cell interactions in the first week of infec- 
tion is dearly critical for resolution of disease. Further evidence 
in support of the role of IL-12 in the generation of a protec- 
tive Thl response is the demonstration that the administra- 
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mally resistant C57B1/6 mice. Depletion of IL-12 profoundly 
affects the ability of these mice to dear the parasite inoculum 
from cutaneous  tissues  and  is  accompanied by a  shift  in 
IFN-3/and IL-4 production, rendering a more Th2-1ike re- 
sponse than in normal rabbit Ig-treated mice (Table 3). Com- 
bined with the ability of IL-12  to augment Thl responses 
in BALB/c mice, these data in C57B1/6 mice indicate that 
IL-12 is critical for the development of a Thl response. 
Earlier studies examining the role of Thl and Th2 cells 
in  the immune response to Leishmania  provided evidence 
demonstrating the key role that IFN-7 plays in modulating 
the Thl response to leishmanial infections. In particular, neu- 
tralizing antibodies to IFN-3' were shown to be capable of 
abrogating protective immunity in genetically resistant mice 
4, 5).  In addition, Thl cells mediating immunity to infec- 
tion produce IFN-% whose expression and secretion directly 
correlates with the reduction in parasite burdens in infected 
resistant mice (1,  2). 
Paradoxically, however, the administration of IFN-7 itself 
after the initiation of infection, although leading to a dday 
in the generation of lesions, ultimately provides no long-term 
control of infection (3, 5). These observations suggest that 
factors in addition to IFN-3  ~  were necessary for the develop- 
ment of a sustained Thl response. We believe the evidence 
provided here strongly suggests that IL-12 is a critical factor 
in initially determining a Thl response. Moreover, the ability 
of IL-12  to directly induce IFN-7 production in both NK 
and T cells (6, 7, 22), in addition to synergizing with other 
physiological IFN-7 inducers, is consistent with IL-12 having 
a key role as a immunopotentiating agent in generating a 
Thl response. Our preliminary observations have also shown 
that the administration of anti-IFN-  7  antibody to infected 
BALB/c mice treated with traiL-12 abrogates their ability 
to initiate a protective immune response (data not shown). 
These data suggest that IL-12 may be influencing the early 
clearance of parasites by initiating a protective Thl response, 
as well as by the induction of IFN-7. 
The murine model of cutaneous leishmaniasis provides an 
excellent system in which to examine the role CD4 + T cells 
and their respective cytokines play in the resolution of patho- 
genesis of infectious diseases. We have shown that IL-12 plays 
a crucial role in initiating a Thl cell response and is essential 
for inducing a protective host immune response. As CD4 + 
subsets become better defined in other disease models, these 
observations will be useful in designing strategies for the de- 
velopment of vaccines and immunotherapy against other in- 
fectious pathogens. 
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